{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:08:49Z","timestamp":1767852529440,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#5R01AI089337-03"],"award-info":[{"award-number":["#5R01AI089337-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5T32AI7493-20"],"award-info":[{"award-number":["5T32AI7493-20"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH-R01-58706"],"award-info":[{"award-number":["NIH-R01-58706"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.virol.2015.10.010","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T17:33:11Z","timestamp":1445707991000},"page":"75-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via \u201cAntigen Capsid-Incorporation\u201d strategy"],"prefix":"10.1016","volume":"487","author":[{"given":"Linlin","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Krendelchtchikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Krendelchtchikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anitra L.","family":"Farrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Derdeyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiana L.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2015.10.010_bib1","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.010_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.010_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"Barouch","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.virol.2015.10.010_bib4","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2015.10.010_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.qai.0000230318.40170.60","article-title":"An adenovirus-based HIV subtype B prime\/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains","volume":"43","author":"Gomez-Roman","year":"2006","journal-title":"J. Acquir. Immune Deficienc. Syndr."},{"key":"10.1016\/j.virol.2015.10.010_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.20778","article-title":"Poxvirus vectors as HIV\/AIDS vaccines in humans","volume":"8","author":"Gomez","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2015.10.010_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virol.2012.02.003","article-title":"Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals","volume":"427","author":"Gorny","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.010_bib8","doi-asserted-by":"crossref","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2015.10.010_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.010_bib10","doi-asserted-by":"crossref","first-page":"e60347","DOI":"10.1371\/journal.pone.0060347","article-title":"Using multivalent adenoviral vectors for HIV vaccination","volume":"8","author":"Gu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2015.10.010_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.virol.2015.10.010_bib12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.virol.2015.10.010_bib13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Julien","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.virol.2015.10.010_bib14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120","volume":"28","author":"Karasavvas","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.virol.2015.10.010_bib15","doi-asserted-by":"crossref","first-page":"20148","DOI":"10.1073\/pnas.1104840108","article-title":"Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer","volume":"108","author":"Liu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2015.10.010_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nm0697-651","article-title":"Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization","volume":"3","author":"Lubeck","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2015.10.010_bib17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/JVI.02006-10","article-title":"The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter","volume":"85","author":"Lynch","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.010_bib18","first-page":"e11815","article-title":"HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach","volume":"5","author":"Matthews","year":"2010"},{"key":"10.1016\/j.virol.2015.10.010_bib19","doi-asserted-by":"crossref","first-page":"e70859","DOI":"10.1371\/journal.pone.0070859","article-title":"Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2","volume":"8","author":"Mayr","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2015.10.010_bib20","doi-asserted-by":"crossref","first-page":"e39045","DOI":"10.1371\/journal.pone.0039045","article-title":"Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of alpha4beta7 binding","volume":"7","author":"Nakamura","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2015.10.010_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion HIV-1 Env","volume":"514","author":"Pancera","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.virol.2015.10.010_bib22","doi-asserted-by":"crossref","first-page":"e33428","DOI":"10.1371\/journal.pone.0033428","article-title":"Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine","volume":"7","author":"Pandey","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2015.10.010_bib23","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/JVI.78.5.2212-2221.2004","article-title":"Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting","volume":"78","author":"Patterson","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.010_bib24","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1128\/JVI.79.16.10200-10209.2005","article-title":"Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies","volume":"79","author":"Peng","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.010_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/psc.719","article-title":"Antigenicity of chimeric and cyclic synthetic peptides based on nonstructural proteins of GBV-C\/HGV","volume":"12","author":"Perez","year":"2006","journal-title":"J. Pept. Sci.: Off. Publ. Eur. Pept. Soc."},{"key":"10.1016\/j.virol.2015.10.010_bib26","doi-asserted-by":"crossref","first-page":"e45840","DOI":"10.1371\/journal.pone.0045840","article-title":"Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens","volume":"7","author":"Ratto-Kim","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2015.10.010_bib27","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.virol.2015.10.010_bib28","doi-asserted-by":"crossref","first-page":"e1000594","DOI":"10.1371\/journal.ppat.1000594","article-title":"Escape from autologous neutralizing antibodies in acute\/early subtype C HIV-1 infection requires multiple pathways","volume":"5","author":"Rong","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2015.10.010_bib29","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1172\/JCI39812","article-title":"Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice","volume":"120","author":"Shiratsuchi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.virol.2015.10.010_bib30","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/infdis\/jis285","article-title":"Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials","volume":"205","author":"Stephenson","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.010_bib31","doi-asserted-by":"crossref","first-page":"e1001249","DOI":"10.1371\/journal.ppat.1001249","article-title":"Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure","volume":"6","author":"White","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2015.10.010_bib32","doi-asserted-by":"crossref","unstructured":"C.B. Wilen, J.C. Tilton, R.W. Doms, HIV: cell binding and entry Cold Spring Harbor perspectives in medicine, 2, 2012.","DOI":"10.1101\/cshperspect.a006866"},{"key":"10.1016\/j.virol.2015.10.010_bib33","doi-asserted-by":"crossref","first-page":"12775","DOI":"10.1128\/JVI.76.24.12775-12782.2002","article-title":"Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon","volume":"76","author":"Wu","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.010_bib34","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1128\/JVI.79.6.3382-3390.2005","article-title":"Identification of sites in adenovirus hexon for foreign peptide incorporation","volume":"79","author":"Wu","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.010_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2015.10.010_bib36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.virol.2015.10.010_bib37","doi-asserted-by":"crossref","first-page":"e53629","DOI":"10.1371\/journal.pone.0053629","article-title":"Analysis of V2 antibody responses induced in vaccinees in the ALVAC\/AIDSVAX HIV-1 vaccine efficacy trial","volume":"8","author":"Zolla-Pazner","year":"2013","journal-title":"PloS One"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682215004377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682215004377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:33:03Z","timestamp":1758587583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682215004377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":37,"alternative-id":["S0042682215004377"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2015.10.010","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via \u201cAntigen Capsid-Incorporation\u201d strategy","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2015.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}